This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications. Compounded versions are not FDA-approved finished products. Consult a qualified healthcare professional to determine whether GLP-1 therapy is appropriate for you.
If you've spent any time looking into weight loss options in 2026, you've run into semaglutide. It's the active ingredient in Ozempic and Wegovy. It's what people mean when they talk about GLP-1 injections. And you've almost certainly also run into “compounded semaglutide” — usually in the context of a telehealth platform offering it for a fraction of the branded price.
Most of the content that explains this distinction either glosses over the regulatory details or gets into the weeds in ways that aren't useful for someone trying to make a practical decision. This piece is the middle path: what compounded semaglutide actually is, how it legally differs from Wegovy, what the regulatory environment in 2026 means for the people buying it, and what to look for in a platform.
What Compounded Semaglutide Actually Is
Compounding is a legitimate, long-standing practice in pharmacy. A compounding pharmacy takes pharmaceutical ingredients and prepares a medication according to a specific prescription — adjusting dose, delivery format, or formulation to meet a patient's individual needs when commercially available products don't fit. This has always been legal under Section 503A of the Federal Food, Drug, and Cosmetic Act for patient-specific prescriptions filled by licensed pharmacies.
What makes GLP-1 compounding unusual is scale. During the semaglutide and tirzepatide drug shortages of 2023 through 2025, the FDA placed these medications on the Drug Shortage List. That listing gave compounding pharmacies broader legal authority to produce these drugs in larger quantities to address the shortage. Thousands of telehealth platforms launched during this window, offering compounded semaglutide and tirzepatide at a fraction of the branded cost.
The active ingredient in compounded semaglutide is the same as in Wegovy. The critical legal distinction is what that sameness does and doesn't mean. Wegovy is an FDA-approved finished drug — it went through clinical trials, manufacturing standards review, and approval as a specific product. Compounded semaglutide is not an FDA-approved finished drug. It has not been independently evaluated by the FDA for safety or efficacy as a product. The pharmacy is licensed and operates under regulatory oversight, but the specific compounded product is not the same regulatory category as the branded medication.
This distinction lives in the fine print of every telehealth platform's terms of service. Platforms that don't disclose it clearly are the ones that received FDA warning letters for misbranding in early 2026.
The Regulatory Shift That Changed Everything in 2025–2026
The FDA declared the semaglutide shortage resolved on February 21, 2025. Tirzepatide's shortage was resolved on December 19, 2024. When shortages are resolved, the broad compounding authority that existed during the shortage period narrows significantly. The FDA's position is that mass-marketed compounded versions of non-shortage drugs operate outside the intended scope of the compounding exemptions.
This triggered a wave of enforcement. In early 2026, the FDA issued warning letters to more than 30 telehealth compounding platforms for misbranding violations — primarily for language that implied FDA approval of compounded products or misrepresented the compounder identity. Major platforms pivoted: in March 2026, Hims and Hers announced a settlement with Novo Nordisk and exited compounded GLP-1 marketing in favor of branded products.
What this means practically: compounded semaglutide is still available through platforms that are operating carefully within the post-shortage regulatory framework. It is not the same legal landscape as 2024. Platforms that are still operating and holding current LegitScript certification, with named pharmacy partners and transparent terms of service, represent the more defensible end of this market. Platforms with active FDA warning letters or that avoid clearly disclosing compounding status are operating with more exposure.
Compounded vs. Branded: The Honest Cost-Benefit
Branded Wegovy costs approximately $1,350 per month without insurance. Branded Zepbound (tirzepatide for obesity) costs approximately $1,060 to $1,350 per month without insurance. For people who don't have insurance coverage for these medications — which is still the majority of commercially insured adults — those prices are simply not accessible.
Compounded semaglutide through telehealth platforms is available in the $99 to $299 per month range depending on platform, dose level, and delivery format. That price difference is why compounding became as large as it did, and it's why people continue to pursue it even as the regulatory environment has tightened.
The honest trade-off: compounded semaglutide gives you access to the same active ingredient at a fraction of the cost, with the trade-off that the product hasn't gone through the same FDA manufacturing and safety review as the branded version. For a patient working with a licensed clinician who screens for contraindications, monitors progress, and manages dose escalation, this trade-off looks different than it does for someone using a compounded product without any clinical oversight.
Worth knowing: Novo Nordisk launched an FDA-approved oral semaglutide pill (the Wegovy pill) in January 2026, starting at $149 per month through manufacturer direct programs. For people who want an oral format and are willing to accept that starter-dose pricing, the FDA-approved oral option is now at near-parity with some compounded starter prices — without the compounding status trade-off. This wasn't true six months ago.
What to Look For in a Compounded GLP-1 Platform
Not all telehealth compounding platforms are structured the same way. These are the signals that distinguish the more legitimate end of the market.
LegitScript certification is the baseline. It's an independent third-party verification that evaluates telehealth companies against compliance and licensing standards. Major payment processors and advertising platforms require it. No LegitScript certification is a meaningful red flag.
Named medical group separation matters. The telehealth platform should not be the entity making clinical decisions. Platforms that clearly name an independent medical group responsible for prescribing — as MadeMed names Xpedicare, LLC — are more clearly structured than platforms that blur this line.
Named pharmacy partners. The compounding pharmacy is where quality control actually happens. Knowing which specific pharmacy is fulfilling your prescription allows you to research their facility registration, 503A or 503B status, and any regulatory history independently.
Transparent compounding disclosure in the terms of service. Any platform operating in this space should disclose clearly that compounded medications are not FDA-approved finished products. Platforms that disclose this in their own legal documentation — as MadeMed does explicitly in its Terms of Use — are more transparent than those that bury it or omit it.
No active FDA warning letters for misbranding or safety violations. This is verifiable through FDA public records.
How MadeMed Fits Into This Picture
MadeMed is one of the compounded GLP-1 telehealth platforms operating in the post-shortage regulatory environment. It holds LegitScript certification, names Xpedicare, LLC as the independent medical group providing clinical services, names AbsoluteRx and Red Rock Pharmacy as partner compounding pharmacies, and explicitly discloses compounding status in its Terms of Use. Programs start at approximately $99 per month, making it among the lower-priced options with verified legitimacy signals in the current market.
For a full breakdown of the platform, see the MadeMed review. For pricing and enrollment specifics, see the MadeMed pricing and how-it-works guide. For a direct comparison with MEDVi, see the MadeMed vs. MEDVi comparison. If you're looking at side effects specifically before deciding, that breakdown is at MadeMed side effects: what the data shows.
Frequently Asked Questions
Is compounded semaglutide the same as Wegovy?
Compounded semaglutide uses the same active ingredient as Wegovy but is not the same product. Wegovy is an FDA-approved finished drug evaluated for safety and efficacy. Compounded semaglutide is prepared by a compounding pharmacy under a physician's prescription and has not gone through the FDA approval process as a finished product. Compounded medications may differ from branded versions in formulation, inactive ingredients, and quality controls.
Is compounded semaglutide legal in 2026?
The legal status of compounded semaglutide is complex and evolving. The FDA declared the semaglutide drug shortage resolved on February 21, 2025. With the shortage resolved, the broad compounding authority from the shortage period has narrowed. Compounding for individual patients by licensed pharmacies under a valid prescription remains legal under Section 503A in most circumstances, but the regulatory environment is actively shifting. Verify the current compliance status of any platform you're considering before enrolling.
How much does compounded semaglutide cost compared to Wegovy?
Branded Wegovy costs approximately $1,350 per month without insurance. Compounded semaglutide through telehealth platforms is available for significantly less — published prices range from approximately $99 to $299 per month depending on the platform, dose, and delivery format. MadeMed's programs start at approximately $99 per month at entry-level doses.
What should I look for when choosing a compounded GLP-1 telehealth platform?
Key factors: LegitScript certification, named medical group separation, named pharmacy partners, transparent disclosure of compounded medication status in terms of service, and no active FDA warning letters for misbranding or safety violations.
What is the difference between injectable and oral sublingual compounded semaglutide?
Injectable semaglutide is the delivery format studied in the major clinical trials that established GLP-1 efficacy. Oral sublingual compounded semaglutide is taken daily under the tongue, but its pharmacokinetics are not established through the same clinical trial standard. The FDA-approved oral semaglutide pill uses a proprietary absorption technology that compounded oral versions do not replicate.